医学临床研究
  2025年5月4日 星期日           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (3): 434-437    DOI: 10.3969/j.issn.1671-7171.2024.03.032
  论著 本期目录 | 过刊浏览 | 高级检索 |
达格列净联合盐酸二甲双胍治疗2型糖尿病患者的临床疗效
陈先乐, 章春花*
苏州工业园区星海医院内科,江苏 苏州 215000
Efficacy Analysis of Dapagliflozin Combined with Metformin in the Treatment of Patients with Type 2 Diabetes
CHEN Xianle, ZHANG Chunhua
Department of Internal Medicine, Xinghai Hospital, Suzhou Industrial Park, Suzhou Jiangsu 215000
全文: PDF (1147 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨达格列净联合盐酸二甲双胍治疗2型糖尿病(T2DM)患者的临床疗效。【方法】选取2020年9月至2023年9月在本院诊治的87例T2DM患者,采用随机数字表法分为观察组(采用达格列净联合盐酸二甲双胍治疗,n=44)和对照组(采用盐酸二甲双胍治疗,n=43)。比较两组患者治疗前后血糖指标[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、血糖标准差(sDBG)、平均血糖波动幅度(MAGE)]、炎症因子[C反应蛋白(CRP)、肿瘤坏死因子-α(TNF-α)、白细胞介素-6(IL-6)、胱抑素C(cys C)、血清同型半胱氨酸(Hcy)]、内分泌激素指标[空腹胰岛素(Fins)、胰岛β细胞指数(HOMA-β)、胰岛素敏感指数(HOMA-IR)]、氧化应激指标[超氧化物歧化酶(SOD)、过氧化氢酶(CAT)]水平及不良反应发生率。【结果】与治疗前比较,两组患者治疗后FPG、2hPG、HbA1c、sDBG、MAGE及CRP、TNF-α、IL-6、Hcy、cys C水平均下降,且观察组显著低于对照组,差异均有统计学有意义(P<0.05)。与治疗前比较,两组患者治疗后Fins、SOD、CAT水平及HOMA-β均升高,且观察组显著高于对照组;两组治疗后HOMA-IR均下降,且观察组显著低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率为13.64%,与对照组的23.26%比较,差异无统计学意义(χ2=1.341,P=0.247)。【结论】达格列净联合盐酸二甲双胍治疗T2DM患者,可有效降低血糖和炎症因子水平,改善胰岛细胞功能,且安全性良好,值得临床推广应用。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
陈先乐
章春花
关键词 糖尿病,2型/药物疗法二甲双胍/药理学治疗结果    
Abstract:【Objective】To investigate the clinical efficacy of dapagliflozin combined with metformin hydrochloride in the treatment of type 2 diabetes(T2DM). 【Methods】A total of 87 patients with type 2 diabetes treated in our hospital from September 2020 to September 2023 were selected and divided into the observation group(treated with dapagliflozin combined with metformin hydrochloride, n=44) and the control group(treated with metformin hydrochloride, n=43) by random number table method. Fasting blood glucose(FPG), 2 h postprandial blood glucose(2hPG) and glycosylated hemoglobin(HbA1c), blood glucose standard deviation(sDBG), mean blood glucose fluctuation range(MAGE), inflammatory factors [C-reactive protein(CRP), tumor necrosis factor-α(TNF-α), interleukin-6(IL-6), serum homocysteine(Hcy), cystatin C(cys C)], endocrine hormones [fasting insulin(Fins), pancreatic island β cell index(HOMA-β), insulin sensitivity index(HOMA-IR)], oxidative stress level [superoxide dismutase(SOD), catalase(CAT)] and incidence of adverse reactions were compared between the two groups before and after treatment. 【Results】Compared to before treatment, the levels of FPG, 2hPG, HbA1c, sDBG, MAGE, CRP, TNF-α, IL-6, Hcy and cys C in the two groups of T2DM patients decreased after treatment, while the above measurements in the observation group were significantly lower than those in the control group with statistical significance(P<0.05). Fins, SOD, CAT levels and HOMA-β of both groups increased after treatment if compared with before treatment, and their values in the observation group were significantly higher than those in the control group. The HOMA-IR of both groups decreased after treatment, and HOMA-IR level in the observation group was significantly lower than that in the control group. The difference was statistically significant(P<0.05). The incidence of adverse reactions in the observation group was 13.64%, compared with 23.26% in the control group, the difference was not statistically significant(χ2=1.341,P=0.247). 【Conclusion】Dapagliflozin combined with metformin hydrochloride can effectively reduce the levels of blood glucose and inflammatory factors, improve the function of islet cells in the treatment of type 2 diabetes patients, and it is safe and worthy of clinical application.
Key wordsDiabetes Mellitus, Type 2/DT    Metformin/PD    Treatment Outcome
收稿日期: 2024-01-26     
中图分类号:  R587.1  
通讯作者: *E-mail:18120054506@163.com   
引用本文:   
陈先乐, 章春花. 达格列净联合盐酸二甲双胍治疗2型糖尿病患者的临床疗效[J]. 医学临床研究, 2024, 41(3): 434-437.
CHEN Xianle, ZHANG Chunhua. Efficacy Analysis of Dapagliflozin Combined with Metformin in the Treatment of Patients with Type 2 Diabetes. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 434-437.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.03.032     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I3/434
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn